Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) Meeting Abstract
| Authors: | Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; Duruisseaux, M.; Leighl, N.; Weinberg, B. A.; Al-Hallak, M. N.; Joe, A. K.; Adeyemi, S.; Wasserman, E.; Koeman, K. J.; Drilon, A.; O'Reilly, E. M. |
| Abstract Title: | Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S895 |
| End Page: | S896 |
| Language: | English |
| ACCESSION: | WOS:001087480202291 |
| DOI: | 10.1016/j.annonc.2023.09.2567 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1618P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work